<DOC>
	<DOCNO>NCT02261532</DOCNO>
	<brief_summary>The primary objective study evaluate pharmacokinetics TAS-102 single multiple dose Chinese patient solid tumor .</brief_summary>
	<brief_title>A Phase I Study TAS-102 Solid Tumors</brief_title>
	<detailed_description>This open-label , non-randomized , single group Phase 1 study TAS-102 , evaluate pharmacokinetics , safety , antitumor activity . Blood sample perform first cycle ( Day1 Day 12 ) therapy consent patient .</detailed_description>
	<mesh_term>Trifluridine</mesh_term>
	<criteria>1 . Has provide write informed consent prior performance study procedure . 2 . Has definitive histologically cytologically confirm advanced metastatic solid tumor . 3 . Is able take medication orally . 4 . Has adequate organ function ( bone marrow , kidney liver ) . 5 . Has Eastern Cooperative Group ( ECOG ) performance status 0 1 . 1 . Has receive TAS102 . 2 . Has suffer serious complication . 3 . Has unresolved toxicity great equal CTCAE Grade 2 attribute prior therapy . 4 . Has prior gastrectomy . 5 . Is pregnant lactate female male refuse use birth control clinical trial period within 6 month discontinuation study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>